Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2001 2
2003 2
2004 1
2005 2
2006 1
2007 2
2008 3
2009 5
2010 7
2011 7
2012 4
2013 6
2014 7
2015 17
2016 25
2017 13
2018 8
2019 9
2020 7
2021 5
2022 9
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 26940768

131 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
Gan HK, Parakh S, Lee FT, Tebbutt NC, Ameratunga M, Lee ST, O'Keefe GJ, Gong SJ, Vanrenen C, Caine J, Giovannetti M, Murone C, Scott FE, Guo N, Burvenich IJG, Paine C, Macri MJ, Kotsuma M, Senaldi G, Venhaus R, Scott AM. Gan HK, et al. Invest New Drugs. 2022 Aug;40(4):747-755. doi: 10.1007/s10637-022-01237-3. Epub 2022 Apr 11. Invest New Drugs. 2022. PMID: 35404015 Clinical Trial.
Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a.
Burvenich IJG, Parakh S, Lee FT, Guo N, Liu Z, Gan HK, Rigopoulos A, O'Keefe GJ, Gong SJ, Goh YW, Tochon-Danguy H, Scott FE, Kotsuma M, Hirotani K, Senaldi G, Scott AM. Burvenich IJG, et al. Theranostics. 2018 Jul 30;8(15):4199-4209. doi: 10.7150/thno.25575. eCollection 2018. Theranostics. 2018. PMID: 30128047 Free PMC article.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.
Shitara K, Satoh T, Iwasa S, Yamaguchi K, Muro K, Komatsu Y, Nishina T, Esaki T, Hasegawa J, Kakurai Y, Kamiyama E, Nakata T, Nakamura K, Sakaki H, Hyodo I. Shitara K, et al. J Immunother Cancer. 2019 Aug 14;7(1):219. doi: 10.1186/s40425-019-0679-9. J Immunother Cancer. 2019. PMID: 31412935 Free PMC article. Clinical Trial.
Novel anti-EPHA2 antibody, DS-8895a for cancer treatment.
Hasegawa J, Sue M, Yamato M, Ichikawa J, Ishida S, Shibutani T, Kitamura M, Wada T, Agatsuma T. Hasegawa J, et al. Cancer Biol Ther. 2016 Nov;17(11):1158-1167. doi: 10.1080/15384047.2016.1235663. Epub 2016 Sep 21. Cancer Biol Ther. 2016. PMID: 27653549 Free PMC article.
Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105.
Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Barnhart TE, Liu G, Leigh BR, Nickles RJ, Cai W. Hong H, et al. Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):138-48. doi: 10.1007/s00259-011-1930-x. Epub 2011 Sep 10. Eur J Nucl Med Mol Imaging. 2012. PMID: 21909753 Free PMC article.
131 results